217 related articles for article (PubMed ID: 8411067)
1. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups.
Nicholson LV; Johnson MA; Bushby KM; Gardner-Medwin D; Curtis A; Ginjaar IB; den Dunnen JT; Welch JL; Butler TJ; Bakker E
J Med Genet; 1993 Sep; 30(9):728-36. PubMed ID: 8411067
[TBL] [Abstract][Full Text] [Related]
2. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.
Nicholson LV; Johnson MA; Bushby KM; Gardner-Medwin D; Curtis A; Ginjaar IB; den Dunnen JT; Welch JL; Butler TJ; Bakker E
J Med Genet; 1993 Sep; 30(9):745-51. PubMed ID: 8411069
[TBL] [Abstract][Full Text] [Related]
3. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients.
Nicholson LV; Johnson MA; Bushby KM; Gardner-Medwin D; Curtis A; Ginjaar IB; den Dunnen JT; Welch JL; Butler TJ; Bakker E
J Med Genet; 1993 Sep; 30(9):737-44. PubMed ID: 8411068
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy.
Nicholson LV; Johnson MA; Gardner-Medwin D; Bhattacharya S; Harris JB
Acta Neuropathol; 1990; 80(3):239-50. PubMed ID: 2205076
[TBL] [Abstract][Full Text] [Related]
5. A homologue of dystrophin is expressed at the blood vessel membrane of DMD and BMD patients: immunological evidence.
Augier N; Boucraut J; Léger J; Anoal M; Nicholson LV; Voelkel MA; Léger JJ; Pellissier JF
J Neurol Sci; 1992 Feb; 107(2):233-8. PubMed ID: 1564523
[TBL] [Abstract][Full Text] [Related]
6. Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy.
Nicholson LV; Davison K; Johnson MA; Slater CR; Young C; Bhattacharya S; Gardner-Medwin D; Harris JB
J Neurol Sci; 1989 Dec; 94(1-3):137-46. PubMed ID: 2693618
[TBL] [Abstract][Full Text] [Related]
7. Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy.
Muntoni F; Mateddu A; Cianchetti C; Marrosu MG; Clerk A; Cau M; Congiu R; Cao A; Melis MA
J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):26-31. PubMed ID: 8429320
[TBL] [Abstract][Full Text] [Related]
8. Dystrophin or a "related protein" in Duchenne muscular dystrophy?
Nicholson LV; Johnson MA; Davison K; O'Donnell E; Falkous G; Barron M; Harris JB
Acta Neurol Scand; 1992 Jul; 86(1):8-14. PubMed ID: 1519480
[TBL] [Abstract][Full Text] [Related]
9. Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy.
Nicholson LV; Johnson MA; Bushby KM; Gardner-Medwin D
Arch Dis Child; 1993 May; 68(5):632-6. PubMed ID: 8323331
[TBL] [Abstract][Full Text] [Related]
10. Dystrophin analysis in the diagnosis of childhood muscular dystrophy: an immunohistochemical study of 75 cases.
Jay V; Becker LE; Ackerley C; Ray P
Pediatr Pathol; 1993; 13(5):635-57. PubMed ID: 8247961
[TBL] [Abstract][Full Text] [Related]
11. Quantitative and qualitative alterations of dystrophin are expressed in muscle cell cultures of Xp21 muscular dystrophy patients (Duchenne and Becker type).
Mongini T; Doriguzzi C; Palmucci L; Chiadò-Piat L
Eur J Clin Invest; 1996 Apr; 26(4):322-4. PubMed ID: 8732491
[TBL] [Abstract][Full Text] [Related]
12. [Muscular dystrophies detected by immunophenotyping and genotype analysis (mRNA and DNA)].
Lukás Z; Vojtísková M; Fajkusová L; Bednarík J; Kadanka Z; Hájek J; Hermanová M; Vohánka S; Vytopil M
Cesk Patol; 2001 Nov; 37(4):137-45. PubMed ID: 11813630
[TBL] [Abstract][Full Text] [Related]
13. Dystrophin as a diagnostic marker in Duchenne and Becker muscular dystrophy. Correlation of immunofluorescence and western blot.
Voit T; Stuettgen P; Cremer M; Goebel HH
Neuropediatrics; 1991 Aug; 22(3):152-62. PubMed ID: 1944822
[TBL] [Abstract][Full Text] [Related]
14. Manifesting carriers of Xp21 muscular dystrophy; lack of correlation between dystrophin expression and clinical weakness.
Sewry CA; Sansome A; Clerk A; Sherratt TG; Hasson N; Rodillo E; Heckmatt JZ; Strong PN; Dubowitz V
Neuromuscul Disord; 1993 Mar; 3(2):141-8. PubMed ID: 8358239
[TBL] [Abstract][Full Text] [Related]
15. Is the maintainance of the C-terminus domain of dystrophin enough to ensure a milder Becker muscular dystrophy phenotype?
Vainzof M; Takata RI; Passos-Bueno MR; Pavanello RC; Zatz M
Hum Mol Genet; 1993 Jan; 2(1):39-42. PubMed ID: 8490621
[TBL] [Abstract][Full Text] [Related]
16. Duchenne and Becker muscular dystrophies: an Estonian experience.
Talkop UA; Klaassen T; Piirsoo A; Sander V; Napa A; Essenson E; Tammur J; Talvik T
Brain Dev; 1999 Jun; 21(4):244-7. PubMed ID: 10392746
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin.
Bulman DE; Murphy EG; Zubrzycka-Gaarn EE; Worton RG; Ray PN
Am J Hum Genet; 1991 Feb; 48(2):295-304. PubMed ID: 1990838
[TBL] [Abstract][Full Text] [Related]
18. Genetic epidemiology of Duchenne and Becker muscular dystrophy in Slovenia.
Peterlin B; Zidar J; Meznaric-Petrusa M; Zupancic N
Clin Genet; 1997 Feb; 51(2):94-7. PubMed ID: 9111995
[TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy.
Hodgson S; Hart K; Abbs S; Heckmatt J; Rodillo E; Bobrow M; Dubowitz V
J Med Genet; 1989 Nov; 26(11):682-93. PubMed ID: 2585468
[TBL] [Abstract][Full Text] [Related]
20. Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype.
Morandi L; Mora M; Confalonieri V; Barresi R; Di Blasi C; Brugnoni R; Bernasconi P; Mantegazza R; Dworzak F; Antozzi C
J Neurol Sci; 1995 Oct; 132(2):146-55. PubMed ID: 8543940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
